Duality Biotherapeutics, Inc. (9606.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$106.10 (-28.07%) as of
Key statistics
- Market cap
- 9.70B
- Forward P/E
- -12.55
- EPS (TTM)
- -0.330
- Dividend yield
- 0.00%
- 52-week range
- 102.800 – 376.800
- Revenue (TTM)
- 842.13M
- Profit margin
- -170.82%
- Analyst target
- HK$404.27
- Volume
- 2.84M
About Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; BeOne to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC; and Genentech, Inc. to develop antibody-drug conjugates. The company was incorporated in 2019 and is headquartered in Shanghai, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Shanghai, China
- Employees
- 266
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.